IR-arkiv | Affibody Medical AB

Affibody Medical Investor Relations

Categories:

Navigation:

Regulatory

May 28, 2026

First Patient Dosed in Part B of Phase 1 Study with Affibody’s Radioligand Therapy Candidate ABY-271 in HER2-positive Metastatic Breast Cancer

Stockholm, Sweden, May 28, 2026. Affibody AB (“Affibody”) today announced that the first patient has been dosed in part B of a Phase 1 clinical study with the company’s...

Regulatory

May 27, 2026

Affibody Presents First-in-Human Clinical Imaging Data with ABY-271 in HER2-positive Metastatic Breast Cancer at SNMMI 2026

Stockholm, Sweden, May 27, 2026. Affibody AB (“Affibody”) today announced that initial first-in-human clinical imaging data from the ongoing Phase 1 study with the HER2-targeting Radioligand Therapy (RLT) candidate...

Regulatory

May 25, 2026

Report from Annual General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, May 25, 2026 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...

Regulatory

May 21, 2026

Positive 52-week Phase 2b/3 Data of Izokibep in Psoriatic Arthritis to be Presented at EULAR 2026

Stockholm, Sweden, May 21, 2026. Affibody AB (“Affibody”) today announced that positive 52-week data from a global Phase 2b/3 study of izokibep in psoriatic arthritis (PsA) will be presented...

Regulatory

April 21, 2026

NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend the annual general meeting of the shareholders on Monday...

Regulatory

March 27, 2026

Izokibep Demonstrates Durable Efficacy in Phase 3 Study in Hidradenitis Suppurativa as Presented at AAD 2026

Stockholm, Sweden, March 27, 2026. Affibody AB (“Affibody”) today announced positive 32-week data from a global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa...

Regulatory

February 19, 2026

Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177

Stockholm, Sweden, February 19, 2026. Affibody AB (“Affibody”) today announced that a Letter of Intent (LOI) has been signed with SHINE Technologies, LCC (“SHINE”) as an additional supplier of...

Regulatory

February 17, 2026

Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Stockholm, Sweden, February 17, 2026. Affibody’s licensee Rallybio Corporation (Rallybio) has today announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical study evaluating RLYB116, an innovative, once-weekly,...

Regulatory

January 20, 2026

Affibody Carries Out Fully Guaranteed Rights Issue of SEK 307 Million

Stockholm, Sweden, January 20, 2026. Affibody Medical AB (publ) (“Affibody”) today announced that the Board of Directors, with authorization from the annual general meeting on May 27, 2025, has...